New Analysis from Phase 3 Clarity AD Study Reveals Health and Financial Benefits of Lecanemab

Published Date: 30 Mar 2023

At a willingness-to-pay threshold of $200,000 per QALY gained, the estimated annual cost of lecanemab is $35,678 and $37,351 from the perspective of payer and community, respectively.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Virtual Reality Travel Reduces Cancer Pain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot